Journal ArticleOPEN ACCESS

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

  • Egan A
  • Blind E
  • Dunder K
  • et al.
New England Journal of Medicine (2014) 370(9) 794-797
DOI: 10.1056/nejmp1314078
479Citations
Citations of this article
233Readers
Mendeley users who have this article in their library.

Abstract

After evaluating a safety signal regarding pancreatitis and pancreatic cancer in patients using incretin-based drugs, the Food and Drug Administration and the European Medicines Agency conclude that assertions of a causal association are inconsistent with the data.

Cite

CITATION STYLE

APA

Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014). Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. New England Journal of Medicine, 370(9), 794–797. https://doi.org/10.1056/nejmp1314078

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free